CGEM
Cullinan Therapeutics, Inc.
$13.84
-0.14
(-1.00%)
Mkt Cap
850.58M
Volume
461,295
52W Range
5.68-16.74
Sector
Healthcare
Beta
-0.09
EPS (TTM)
-3.75
P/E Ratio
-2.78
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$33.09
Undervalued · Strong
58.2% below fair value
AlphaQuality · Grade · Gated
F
Stable Earnings Power
27.7 / 100 pillar composite (overridden)
Company Description
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 18.94M | 0 | 0 | 0 |
| Net Income | (219.88M) | (167.38M) | (153.16M) | 111.21M | (65.57M) | (51.80M) | (20.04M) | (14.19M) |
| EPS | -3.72 | -3.11 | -3.69 | 2.46 | -1.48 | -1.19 | -19.70 | -17.74 |
| Free Cash Flow | (175.80M) | (145.30M) | (134.48M) | (127.80M) | (44.02M) | (29.78M) | (20.92M) | (13.81M) |
| FCF / Share | -2.98 | -2.70 | -3.24 | -2.83 | -0.99 | -0.68 | -20.57 | -17.26 |
| Operating CF | (175.75M) | (145.30M) | (134.28M) | (126.66M) | (43.43M) | (29.77M) | (20.90M) | (13.55M) |
| Total Assets | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M | 214.71M | 100.46M | 34.64M |
| Total Debt | 2.68M | 2.15M | 3.59M | 5.19M | 0 | 0 | 0 | 0 |
| Cash & Equiv | 88.33M | 83.00M | 98.43M | 156.15M | 59.77M | 168.20M | 63.25M | 33.83M |
| Book Value | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M | 199.01M | (40.77M) | (20.65M) |
| Return on Equity | -0.54 | -0.28 | -0.34 | 0.21 | -0.15 | -0.26 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.66M) | (50.71M) | (50.61M) | (70.06M) | (48.50M) | (47.65M) | (40.56M) | (42.03M) | (37.15M) | (23.80M) | (39.18M) | (32.21M) |
| EPS | -0.84 | -0.86 | -0.86 | -1.19 | -0.82 | -0.81 | -0.70 | -0.76 | -0.86 | -0.56 | -0.92 | -0.81 |
| Free Cash Flow | (46.05M) | (38.12M) | (36.91M) | (57.61M) | (43.16M) | (36.63M) | (34.14M) | (36.29M) | (38.25M) | (18.13M) | (34.14M) | (31.05M) |
| FCF / Share | -0.78 | -0.64 | -0.63 | -0.98 | -0.73 | -0.63 | -0.59 | -0.66 | -0.89 | -0.42 | -0.80 | -0.78 |
| Operating CF | (46.05M) | (38.11M) | (36.88M) | (57.61M) | (43.16M) | (36.63M) | (34.14M) | (36.29M) | (38.25M) | (18.13M) | (34.14M) | (31.01M) |
| Total Assets | 402.98M | 448.37M | 484.13M | 520.33M | 579.68M | 621.82M | 653.25M | 681.22M | 449.43M | 484.18M | 494.71M | 521.98M |
| Total Debt | 2.38M | 2.68M | 1.19M | 1.52M | 1.84M | 2.15M | 2.45M | 2.73M | 3.17M | 3.59M | 5.92M | 6.27M |
| Cash & Equiv | 75.08M | 88.33M | 103.33M | 72.82M | 76.66M | 83.00M | 102.08M | 115.02M | 74.23M | 98.43M | 64.85M | 141.83M |
| Book Value | 366.17M | 408.73M | 451.37M | 492.15M | 551.84M | 590.33M | 627.86M | 656.22M | 425.67M | 453.70M | 468.82M | 499.57M |
| Return on Equity | -0.14 | -0.12 | -0.11 | -0.14 | -0.09 | -0.08 | -0.06 | -0.06 | -0.09 | -0.05 | -0.08 | -0.06 |
CGEM News
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
The Biology Came First.
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference